Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Angriffe auf Aluminiumhütten im Nahen Osten treiben Aktien von Alcoa und Century an (Investing.com DE) +++ ALCOA Aktie +3,27%

EXACT SCIENCES Aktie

 >EXACT SCIENCES Aktienkurs 
90.74 EUR    +1.4%    (TradegateBSX)
Ask: 90.93 EUR / 0 Stück
Bid: 90.52 EUR / 0 Stück
Tagesumsatz: 16 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>EXACT SCIENCES Performance
1 Woche: 0%
1 Monat: +2,1%
3 Monate: +4,8%
6 Monate: +101,5%
1 Jahr: +127,5%
laufendes Jahr: +4,8%
>EXACT SCIENCES Aktie
Name:  EXACT SCIENCES
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US30063P1057 / 590273
Symbol/ Ticker:  EXK (Frankfurt) / EXAS (NASDAQ)
Kürzel:  FRA:EXK, ETR:EXK, EXK:GR, NASDAQ:EXAS
Index:  -
Webseite:  https://www.exactsciences..
Profil:  Exact Sciences Corp is a leading molecular diagnostics company specializing in cancer screening and diagnostic tests. Its flagship product, Cologuard, is a non-invasive stool-based DNA test designed to detect colorectal cancer and pre-cancer through ..
>Volltext..
Marktkapitalisierung:  17315.12 Mio. EUR
Unternehmenswert:  18640.04 Mio. EUR
Umsatz:  2807.44 Mio. EUR
EBITDA:  56.98 Mio. EUR
Nettogewinn:  -179.8 Mio. EUR
Gewinn je Aktie:  -0.96 EUR
Schulden:  2191.66 Mio. EUR
Liquide Mittel:  826.58 Mio. EUR
Operativer Cashflow:  424.91 Mio. EUR
Bargeldquote:  1.5
Umsatzwachstum:  3.74%
Gewinnwachstum:  82.19%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  EXACT SCIENCES
Letzte Datenerhebung:  01.04.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 190.89 Mio. St.
Frei handelbar: 98.41%
Leerverk. Aktien: -
Rückkaufquote: -0.14%
Mitarbeiter: 7200
Umsatz/Mitarb.: 0.39 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: -0.55%
Bewertung:
KGV: -
KGV lG: -
KUV: 6.05
KBV: 8.48
PEG-Ratio: -
EV/EBITDA: 327.14
Rentabilität:
Bruttomarge: 69.69%
Gewinnmarge: -6.4%
Operative Marge: -4.79%
Managementeffizenz:
Gesamtkaprendite: -3.39%
Eigenkaprendite: -8.66%
>Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung
 
27.03.26 - 20:51
Deal Dispatch: Estée Lauder Considers Merger, KKR Buys Nothing Bundt Cakes, Amazon Acquires Fauna Robotics (Benzinga)
 
Major M&A deals this week: Corebridge Financial acquires Equitable Holdings for $22 billion, Abbott acquires Exact Sciences. Importance Rank:  1 read more...
24.03.26 - 21:48
XFRA: Deletion of Instruments from Boerse Frankfurt - 24.03.2026 (XETRA)
 
The following instruments on Boerse Frankfurt do have their last trading day on 24.03.2026. Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.03.2026. ISIN Name CA4013392051 GUARDIAN CAPITAL GRP CA4013393042 GUARDIAN CAP. GRP A FR0010907956 CARMAT EO -,04 LU0934195610 ROB.GL.T.R.BD F.DH EO NO0013671115 INTL PETROL 25/30 US30063P1057 EXACT SCIEN. DL-,01 US5834352016 STEAKHOLDER F.NEW ADR/100 US68237Q2030 ONCONETIX INC. US98386D3070 XTL BIOPHARMA. ADR 100 XS3307259237 IBERDROLA FINANZAS S.A....
23.03.26 - 13:54
Abbott completes acquisition of Exact Sciences (PR Newswire)
 
Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments Advances Abbott's mission to make healthcare more accessible and give people more control over their health ABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has......
23.03.26 - 08:27
XFRA: EXK: Aussetzung/Suspension (XETRA)
 
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL EXACT SCIEN. DL-,01 EXK US30063P1057 BAW/UFN...
23.03.26 - 08:27
XFRA: ZERTIFIKATEBOERSE SUSPENSION OF UNDERL.: US30063P1057 (XETRA)
 
ALLE STRUKTURIERTEN PRODUKTE MIT UNDERLYING US30063P1057 SIND AB SOFORT VOM HANDEL AUSGESETZT BIS AUF WEITERES. ALL STRUCTURED PRODUCTS WITH UNDERLYING US30063P1057 ARE SUSPENDED UNTIL FURTHER NOTICE....
23.03.26 - 08:01
XFRA: INSTRUMENT_SUSPENSION - US30063P1057 (XETRA)
 
Instrument ID [8401] (EXK - US30063P1057) suspended...
20.03.26 - 14:03
Abbott acquisition of Exact Sciences set to close on March 23, 2026 (PR Newswire)
 
Announcement follows receipt of all regulatory clearances necessary for closing Transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional people ABBOTT PARK, Ill., March 20, 2026 /PRNewswire/ -- Abbott (NYSE:......
11.03.26 - 16:30
Exact Sciences (EXAS) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
 
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....
03.03.26 - 16:03
KeyCare Raises $27.4 Million to Scale their AI-Powered, Epic-Based Virtual Care Solution for Health Systems (Business Wire)
 
Led by HealthX Ventures, the round will accelerate development of KeyCare's AI-enabled virtual care as demand for access to high-quality, coordinated virtual care continues to surgeCHICAGO--(BUSINESS WIRE)--KeyCare, the nation's first Epic-based virtual care company, today announced the close of a $27.4M financing round. The most recent round was led by HealthX Ventures and included participation from 8VC, LRVHealth, BOLD Capital Partners, and Ikigai Venture Partners. Additionally, this financing included a variety of strategic partners, such as WellSpan Health, Allina Health, University of Chicago Ventures, Edge Ventures (investment arm of Emplify Health), and Exact Sciences, Inc. This latest funding round brings KeyCare's total capital raised to over $55 million. KeyCare's virtual care medical group, working on their optimized instance of Epic, has become a trusted primary care extension partner for health systems - allowing for easy patient access that improves access and quality of care. Through a...
23.02.26 - 17:12
Abbott eyes $20B bond sale to fund purchase of Exact Sciences - report (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
23.02.26 - 15:18
Abbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal (Bloomberg)
 
Abbott Laboratories is selling corporate bonds in as many as eight parts to help fund its around $21 billion acquisition of cancer-screening company Exact Sciences Corp....
20.02.26 - 22:21
Exact Sciences shareholders approve acquisition by Abbott (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
20.02.26 - 22:09
Exact Sciences Stockholders Approve Acquisition by Abbott (Business Wire)
 
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Sciences common stock as of the January 9, 2026 record date for the special meeting, were voted in favor of the transaction. Final voting results from the special meeting will be reported by Exact Sciences in a Current Report on Form 8‑K filed with the U.S. Securities and Exchange Commission (the “SEC”). Subject to the satisfaction or waiver of the remaining conditions to closing, the transaction is expected to close before the end of the second calendar quarter of 2026. Under the terms of the definitive agree...
19.02.26 - 16:00
Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up (Zacks)
 
EXAS posts Q4 revenue beat as Screening and Precision Oncology grow, margins expand, shares tick up and Abbott merger plans progress....
14.02.26 - 01:00
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
 
Exact Sciences (EXAS) delivered earnings and revenue surprises of -8,300.00% and +2.07%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...
13.02.26 - 23:54
Exact Sciences Q4 Loss Narrows As Revenues Gain (AFX)
 
WASHINGTON (dpa-AFX) - Exact Sciences Corporation (EXAS) on Friday, reported higher revenue for both the fourth quarter and full year ended December 31, 2025, while significantly narrowing its los......
13.02.26 - 22:09
Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results (Business Wire)
 
Fourth quarter and 2025 highlights Total fourth quarter revenue of $878 million, an increase of 23% on a reported and core revenue basis, with Screening revenue of $695 million and Precision Oncology revenue of $183 million Total 2025 revenue of $3.25 billion, an increase of 18% on a reported and core revenue basis, with Screening revenue of $2.53 billion and Precision Oncology revenue of $717 million Operating cash flow was $491 million and free cash flow was $357 million for the full-year 2025, an improvement of 133% and 379%, respectively Net loss was $208 million and adjusted EBITDA was $400 million for the full-year 2025, an improvement of $821 million and $77 million, respectively MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $878 million for the fourth quarter of 2025 and $3.25 billion for the full year of 2025, both ended December 31, 2025. “In 2025 the Exact ...
06.02.26 - 19:39
Exact Sciences ticks higher amid reports HSR for Abbott deal expired (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
20.01.26 - 19:06
Assessing Exact Sciences: Insights From 16 Financial Analysts (Benzinga)
 
Latest Ratings for EXAS DateFirmActionFromTo Feb 2022Wells FargoMaintainsEqual-Weight Feb 2022CitigroupMaintainsNeutral Feb 2022Raymond JamesMaintainsOutperform View More Analyst Ratings for EXAS View the Latest Analyst Ratings read more...
20.01.26 - 14:00
Here Are Tuesday′s Top Wall Street Analyst Research Calls: Chevron, Domino’s Pizza, Doximity, Exact Sciences, Intel, NetApp, StubHub, Toast, and More (24/7 Wall St.)
 
Pre-Market Stock Futures: Futures are trading dramatically lower as we start the holiday-shortened trading week, following yesterday's MLK remembrance day. The futures downdraft this morning is being attributed to President Trump's threat to raise tariffs significantly over Greenland. Last Friday, the market closed unchanged primarily after a sizable options expiration that boosted trading volume throughout ... Here Are Tuesday's Top Wall Street Analyst Research Calls: Chevron, Domino's Pizza, Doximity, Exact Sciences, Intel, NetApp, StubHub, Toast, and More The post Here Are Tuesday's Top Wall Street Analyst Research Calls: Chevron, Domino's Pizza, Doximity, Exact Sciences, Intel, NetApp, StubHub, Toast, and More appeared first on 24/7 Wall St.....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Es gibt einen Tag, um geboren zu werden, und einen Tag, um zu sterben. - China Weisheit
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!